Prospective clinical studies using somatostatin or its analogue octreotide in human acute pancreatitis
| Reference | Study design | Drug/dosage | Number of patients | Complications | Mortality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls | Treatment | Controls | Treatment | ||||||||||
| Gjorup and colleagues40 | RCT, | Somatostatin | 63 | 30% (9/30) | 42% (14/33) | 3% (1/30) | 3% (1/33) | ||||||
| multicentre | 250 μg/h for 3 days | ||||||||||||
| Luengo and colleagues41 | RCT | Somatostatin | 100 | NA | NA | 2% (1/50) | 2% (1/50) | ||||||
| 250 μg/h for 48 h | |||||||||||||
| Beechey-Newman42 | Open | Octreotide | 19 | NA | NA | 0% | 0% | ||||||
| 0.5 μg/kg/h for 10 days | |||||||||||||
| O’Hair and colleagues43 | RCT | Octreotide 100 μg t.i.d. | 180 | 10% (9/90) | 3% (3/90) | 0% | 1% (1/90) | ||||||
| s.c. until discharge | |||||||||||||
| Paran and colleagues44 | Open | Octreotide 100 μg t.i.d. | 38 | 74% (14/19) | 26% (5/19)† | 31% (6/19) | 10.5% (2/19) | ||||||
| s.c. for 14 days | 63% (12/19) | 37% (7/19)‡ | |||||||||||
| Fiedler and colleagues45 | Case controlled | Octreotide 100 μg t.i.d. | 93 | 87% (47/59) | 51% (26/39)§ | 61% (33/54) | 26% (10/39)4-150 | ||||||
| i.v. for 10 days | 40% (21/59) | 18% (7/39)¶ | |||||||||||
| McKay and colleagues46 | RCT, | Octreotide 40 μg/h | 58 | 37% (11/30) | 53% (15/28) | 20% (6/30) | 18% (5/28) | ||||||
| multicentre | i.v. for 5 days | ||||||||||||
| Present study | RCT, | Octreotide 100 μg t.i.d. | 302 | 71% (73/103) | 76% (74/98) | 16% (16/103) | 15% (15/98) | ||||||
| multicentre | s.c. for 7 days | ||||||||||||
| Octreotide 200 μg t.i.d. | 71% (73/103) | 72% (73/101) | 16% (16/103) | 12% (12/101) | |||||||||
| s.c. for 7 days | |||||||||||||
RCT, randomised controlled trial; NA, not assessed.
↵4-150 p<0.05; †sepsis, p=0.004; ‡ARDS, p=0.1; §shock, p<0.05; ¶ARDS, p<0.05.